Navigation Links
Study evaluates use of inhaled saline for young children with cystic fibrosis
Date:5/20/2012

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis (CF). Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with CF, but its efficacy has not been evaluated in patients younger than 6 years.

In the randomized trial, the active treatment group (n = 158) received 7 percent hypertonic saline and the control group (n = 163) received 0.9 percent isotonic saline, nebulized (dispensed in a fine mist) twice daily for 48 weeks. The researchers found that the average pulmonary exacerbation rate was similar between both groups. "Hypertonic saline did not reduce the rate of pulmonary exacerbations in these young children. In addition, hypertonic saline did not demonstrate any significant effects on secondary end points including weight, height, respiratory rate, oxygen saturation, antibiotic use, or parent report of respiratory signs and symptoms."


'/>"/>

Contact: Mary Guiden
mary.guiden@seattlechildrens.org
206-987-7334
JAMA and Archives Journals
Source:Eurekalert

Page: 1

Related medicine news :

1. Study says children exposed to tobacco smoke face long-term respiratory problems
2. One-Third of U.S. Homeless Population Is Obese: Study
3. Military Marriages Stay Strong in Face of Challenges: Study
4. Its Not Just What You Eat, Its When You Eat, Mouse Study Finds
5. Parents Often Lose Sleep Over Childs Epilepsy, Study Finds
6. OSHAs Safety Tests Protect Workers at Little Cost: Study
7. Scientists study serious immune malfunction
8. Study Explores Distractions Role in Pain Relief
9. Early Study Hints at Link Between Certain Sunscreens, Endometriosis
10. Researchers undertake radical new cancer survivorship study
11. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , a ... today announced Cumberland Skin Surgery and Dermatology has joined the company ... in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer ...
(Date:8/16/2017)... Island, NY (PRWEB) , ... August 16, 2017 , ... ... with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical ... takes much of the guesswork out of a needle stick and more importantly, helps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , is honored ... The annual list identifies the nation’s top physicians, in a variety of specialties. This ... the top of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... states: “Drying the endoscope after every reprocessing cycle, both between patient procedures and ... and nosocomial infections. Drying is as important to the prevention of disease transmission ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/28/2017)... 2017 EnvoyHealth, a Diplomat company, has partnered with ... CleverCap LITE, a technology designed to improve patient medication ... health technology solutions and services that help track and ... CleverCap LITE offers medication monitoring and control for ... Records date and time ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: